tirzepatide losing effectiveness Is a Game-Changer in Medical Weight Loss Treatment? Tirzepatide Explained: The Future of

People with impaired FMO3 activity either due to genetic variants known to cause trimethylaminuria or due to liver disease have reduced ability to clear TMA

God: King Neptune is pretty much Bikini Bottom's equivalent of God

Photograph the vial against a white background

Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al

--- This year brought 26 biosimilars that were approved by the FDA A significant portion of them (16) were denosumab biosimilars: 8 biosimilars referencing Prolia (denosumab for osteoporosis) Additional 8 biosimilars referencing Xgeva (denosumab for cancer-related bone disease) The downstream effects compound: Biosimilars typically reduce costs by 15-35% compared to reference products (this can decrease more as additional biosimilar options become available) Price competition benefits the entire therapeutic category Patients who couldn't afford brand therapy now have accessible options Health systems gain formulary flexibility without compromising clinical outcomes --- The 26 biosimilar approvals in 2025 represent thousands of patients gaining affordable access to proven therapies that may have previously been out of reach

Positive pipeline milestones or favorable reimbursement developments that bolster the long-term growth narrative